Generic Name: Vancomycin HCl
Brand Name: Vancocin CP
Formulation:
Each vial contains sterile vancomycin hydrochloride equivalent to 500mg vancomycin activity. Vancomycin hydrochloride is an off-white lyophilized plug. When reconstituted in water, it forms a clear solution with a pH range of 2.5 to 4.5
Indications:
Vancomycin hydrochloride is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporin, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly.
Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by Streptococcus viridansor S. bovis. For endocarditis caused by enterococci (e.g. E. faecalis), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside.
Vancomycin hydrochloride has been reported to be effective for the treatment of diptheroid endocarditis.
Vancomycin hydrochloride has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidisor diptheroids.
Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin hydrochloride.
The parenteral form of vancomycin hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembraneous colitis caused by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is unproven benefit for these indications. Vancomycin hydrochloride is not effective by the oral route for other types of infection.
Although no controlled clinical efficacy studies have been conducted, intravenous vancomycin has been suggested by the American Heart Association and the American Dental Association as prophylaxis against bacterial endocarditis in penicillin-allergic patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when these patients undergo dental procedures or surgical procedures of the upper respiratory tract.
Note: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association.